
The biopharm division at Novo Nordisk could not live up to the progress achieved in the first 6 months of 2021 during Q3.
In its quarterly report, the pharmaceutical company reveals that the segment has brought in DKK 4.5bn (USD 700m), equating to a small regression of 2 percent. This comes after a drop in sales on the North American, European and Middle Eastern markets, which has undermined the positive developments in the rest of the world, for example in China, where the business arm is still new, and relatively small, but experiencing explosive growth. This market has provided DKK 121m (USD 18.8m) in sales so far this year, double that of the sales revenue for the same period last year.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
In a world of options, Genmab's CEO chose partnerships
In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.